November 11, 2019 06:42 AM EST
Deals

An Is­raeli biotech gam­bles on a failed drug, merg­ing with trou­bled Men­lo ahead of PhI­II da­ta

John Carroll

Editor & Founder

Af­ter tak­ing a pair of tor­pe­does at the wa­ter­line last year, a list­ing Men­lo Ther­a­peu­tics $MN­LO is cast­ing its lot with Is­raeli der­ma­tol­ogy biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

Pfiz­er ends work on Sang­amo's he­mo­phil­ia gene ther­a­py, crush­ing biotech's hopes

A look at biotech's year of the megaround

Flag­ship biotech Va­lo Health ends 2024 with mid-stage fail

No­var­tis ends Phase 1 ra­dio­phar­ma tri­al; Solve Ther­a­peu­tics pur­sues $75M round

A service from the Financial Times